Group 1 - Structure Therapeutics Inc. reported positive results from its phase 2a study of GLP-1R agonist GSBR-1290 for obesity treatment, leading to a phase 2b study initiation in Q4 2024 [1] - The company successfully transitioned from a capsule to a tablet formulation, achieving effective once-daily dosing for weight loss [1] Group 2 - The company plans to combine GLP-1R agonist with other drugs from its pipeline, including APJR agonist ANPA-0073, GIPR selective agonist, and amylin receptor agonist [2] - ANPA-0073 is being developed not only for obesity but also for idiopathic pulmonary fibrosis (IPF), targeting a significant multibillion-dollar market [2] - The development of LPA1R agonist LTSE-2578 for IPF treatment is underway, with a phase 1 randomized study initiated in June 2024 [2] - The company has sufficient cash to progress through several milestones in its development pipeline [2]

Group 1: Company Strategy - Novartis is adopting a strategic approach to growth, opting not to participate in the competitive weight loss drug market, which has a market potential of $200 billion [1][2] - CEO Vas Narasimhan emphasized focusing on opportunities with higher odds of success rather than joining the current "frenzy" in the weight loss sector [3] - The company is targeting areas such as radioligand cancer therapies, which could build a $20 billion business, and treatments for neurodegenerative diseases like Parkinson's, Huntington's, and Alzheimer's [4][5] Group 2: Financial Performance - Novartis' stock has increased by 15% this year, which is lower than the S&P 500's 22% gain, but this has resulted in a more modest valuation with shares trading at 14 times expected future earnings [7] - The company's projected annual sales growth is 5% through 2027, which, while not overly exciting, helps manage future expectations [8] Group 3: Investment Appeal - Novartis is considered a potentially underrated growth stock, appealing to risk-averse investors seeking growth opportunities [9] - The stock offers a dividend yield of 3.3%, significantly higher than the S&P 500 average of 1.3%, making it an attractive long-term investment option [10]

Wisp debuts its first-ever exclusive over-the-counter weight-loss supplement, designed to promote women's metabolic health. Wisp introduces personalized, online consultations with access to four weight care solutions, including GLP-1 medications, to support women struggling with hormonal conditions such as perimenopause, menopause, Polycystic Ovary Syndrome (PCOS), and endometriosis. With over 1.2 million patients, Wisp Now Also Bolsters its Menopause Solutions, Empowering Women Through All Major Stages of ...

The future of the weight loss market might not revolve around GLP-1 drugs. By now, nearly everyone has heard of the weight loss drugs targeted at the glucagon-like protein 1 (GLP-1) receptor, like Zepbound and Wegovy by Eli Lilly and Novo Nordisk, respectively. It's no surprise why they're household names; those medicines are bringing in billions of revenue every quarter, driving share prices up relentlessly along the way. However, GLP-1-based therapies aren't going to be the only option in the weight loss ...

GLP Group has announced the merger of its fund management business, GLP Capital Partners (GCP), with Ares Management Corporation, a leading alternative asset management company listed on the New York Stock Exchange. The merger includes GCP's international operations in Japan, the United States, Europe, Brazil, and Vietnam. The transaction is valued at a total of $5.2 billion, which consists of an initial consideration of $3.7 billion and a potential additional payout of up to $1.5 billion tied to performanc ...

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonists Elevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets Licensed Product / Nation Patent Application Serial No. Title: Pharmaceutical composition for alleviation, treatment, and prevention of sarcopenia containing microorganism transformed with cell surface display ...

Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, "TRIM," a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies. Tirzepatide, a dual GIP ...

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonists Elevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets Licensed Product / Nation Patent Application Serial No. Title: Pharmaceutical composition for alleviation, treatment, and prevention of sarcopenia containing microorganism transformed with cell surface display ...

Gain access to all of the market research and financial analytics used in the preparation of this article plus exclusive content and pharma, healthcare and biotech investment recommendations and research / analytics by subscribing to my channel, Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, ...

Core Insights - Entera Bio Ltd. and OPKO Health, Inc. announced positive topline pharmacokinetic/pharmacodynamic results from their collaboration on a proprietary long-acting oxyntomodulin (OXM) analog, aimed at developing the first oral dual agonist GLP-1/glucagon peptide for treating obesity and metabolic disorders [1][2] Group 1: Collaboration and Research Progress - The collaboration has successfully completed in vivo proof-of-concept PK/PD studies in rodent and pig models, demonstrating significant systemic exposure and favorable pharmacokinetic profiles for oral OXM [2][3] - A glucose tolerance test in rats showed that oral OXM significantly reduced plasma glucose levels compared to placebo, indicating its potential efficacy [3][4] Group 2: Product Development and Market Potential - Entera is developing the first oral oxyntomodulin in tablet form, which could provide a non-injection alternative for obesity treatment, addressing a significant unmet medical need [6] - OPKO's previous studies indicated that weekly injections of pegylated OXM led to significant weight loss and improvements in metabolic markers among obese and diabetic patients, highlighting the therapeutic potential of OXM [5] Group 3: Company Profiles - Entera Bio is focused on developing oral peptide therapies for unmet medical needs, with a pipeline that includes five first-in-class oral peptide programs expected to enter clinical trials by 2025 [6] - OPKO Health is a multinational biopharmaceutical company aiming to establish leading positions in rapidly growing markets through its proprietary technologies and expertise in drug development [7]